TD 9855

Drug Profile

TD 9855

Alternative Names: TD-9855

Latest Information Update: 08 Jun 2016

Price : $50

At a glance

  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Analgesics
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Orthostatic hypotension
  • No development reported Fibromyalgia
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 May 2016 Phase-II clinical trials in Orthostatic hypotension (In adults; In the elderly) in USA (PO) (NCT02705755)
  • 07 Mar 2016 Theravance Biopharma plans a phase II trial for Orthostatic hypotension (In adults, In the elderly) in USA (PO) (NCT02705755)
  • 22 Jan 2016 Phase-I/II clinical trials in Orthostatic hypotension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top